With the approval of transcatheter aortic valve replacement (TAVR) for patients with severe symptomatic aortic stenosis at intermediate surgical risk, TAVR volume is projected to increase exponentially in the United States. The 30-day readmission rate for TAVR was recently reported at 17.9%. The association between institutional TAVR volume and the 30-day readmission metric has not been examined.
T ranscatheter aortic valve replacement (TAVR) is guideline recommended for patients with symptomatic severe aortic stenosis at prohibitive risk or "selected" patients at high conventional surgical risk. [1] [2] [3] [4] [5] [6] The volume of TAVR has been increasing worldwide, with TAVR surpassing conventional surgical aortic valve replacements in some European nations. 7, 8 With the recent US Food and Drug Administration approval of the Edwards Sapien XT and Sapien 3 valves (Edwards Lifesciences) for intermediate surgical risk patients, the use of TAVR is expected to increase exponentially in the United States. 9,10 Improved case selection and procedural and technical refinements coupled with operator experience have led to better TAVR outcomes in the United States; however, TAVR programs (irrespective of experience or volume) are under constant pressure to further improve outcome metrics.
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Readmission is a frequently used quality metric, especially in the realm of cardiovascular diseases and procedures (heart failure, acute myocardial infarction, coronary artery bypass graft surgery, and percutaneous coronary intervention).
12
The most recent data from elderly Medicare beneficiaries reported a 17.8% readmission rate for targeted conditions (acute myocardial infarction, heart failure, and pneumonia). 13 Rising health care expenditures have led hospital systems and practices to track outcomes and expenditures, especially for novel procedures. In prior studies, the 30-day readmission rate for TAVR was reported at 17.9% and high-volume TAVR hospitals have been shown to have lower in-hospital mortality, shorter length of stay (LOS), and reduced hospital costs. [14] [15] [16] However, to our knowledge, there are no data from the US TAVR experience assessing the association between hospital TAVR volume and 30-day readmission rates. We designed this observational study to assess 30-day readmission rates at low-, medium-, and high-volume TAVR hospitals and to compare the causes and cost of readmission.
Methods

Data Source
The 2014 Nationwide Readmissions Database (NRD) was used for this study. The NRD is part of a family of databases developed by the Agency for Healthcare Research and Quality for the Healthcare Cost and Utilization Project. The 2014 NRD is constructed from the State Inpatient Databases of 22 states that are geographically dispersed and represent 51.2% of the total US resident population and 49.3% of all US hospitalizations. Unweighted, the NRD contains data from approximately 15 million discharges each year. Weighted, it estimates approximately 35 million discharges. Weighting of data by applying the DISCWT variable was done to obtain national estimates. The NRD contains clinical and nonclinical variables that support readmission analyses, while protecting the privacy of individual patients, physicians, and hospitals. This study was deemed exempt from institutional review board approval by the New York Medical College institutional review board because the NRD is publicly available and contains deidentified patient data.
Study Population
Hospitalizations for TAVR were identified using the International Classification of Diseases, Ninth Revision, Clinical Modification procedure codes 35.05 and 35.06. A total of 241 hospitals performed TAVRs in 2014. Hospitals with an established TAVR program (defined as performing at least 5 TAVRs in the first quarter of 2014) were identified (n = 129) and included in the present study. These hospitals performed 18 601 TAVRs in 2014. Based on the annual number of TAVRs performed, hospitals were categorized as low-volume (<50), medium-volume (≥50 to <100), and high-volume (≥100) hospitals. These cutoffs were determined based on the median TAVR volume in our study cohort (97 TAVRs per year). We categorized highvolume hospitals as those above the median and subdivided the ones below the median into 2 groups: low and medium. The Centers for Medicare and Medicaid Services do not provide cutoffs for hospital classification as low-, medium-, or high-volume TAVR hospitals. Moreover, the goal of this study was not to identify ideal TAVR volume cutoffs as TAVR is still an evolving field and institutional volumes are likely to increase in the future. We excluded hospitals that did not perform at least 5 TAVRs in the first quarter to avoid confounding data from nonestablished TAVR programs. A total of 1049 TAVRs were performed in these excluded hospitals in 2014, with a median of 3 TAVRs per center (interquartile range, 2-16). Because the primary outcome of interest was 30-day readmissions, patients discharged in December 2014 (n = 1698) were excluded owing to lack of follow-up data. We also excluded patients who died during the index hospitalization (n = 647 [in-hospital mortality = 3.8% overall and 4.3%, 4.4%, and 3.7% in low-, medium-, and high-volume hospitals, respectively]). For patients who underwent repeat TAVR within 30 days (n = 4), the second discharge record was considered a readmission. On the other hand, for patients who underwent repeat TAVR after 30 days (n = 38), the second discharge record was considered a separate index procedure. The final study sample consisted of 16 252 index TAVRs performed at 129 hospitals ( Figure 1) . disease, prior transient ischemic attack [TIA]/stroke, atrial fibrillation, prior permanent pacemaker, prior implantable cardioverter defibrillator, peripheral vascular disease, anemia, chronic kidney disease, chronic lung disease, liver disease, coagulopathy, dementia, depression, hypothyroidism, fluid and electrolyte disorders, other neurological disorders, pulmonary circulation disorders, and cancer). Hospital characteristics, such as location, teaching status, and bed size, were also examined. Other variables extracted were TAVR access site (endovascular [EV] vs transapical [TA]), in-hospital procedures (coronary angiography, percutaneous coronary intervention, and mechanical circulatory support), and in-hospital complications (conversion to surgical aortic valve replacement, complete heart block, permanent pacemaker placement, TIA/ stroke, acute myocardial infarction, cardiogenic shock, cardiac arrest, acute kidney injury, major bleeding, and vascular complications). The Healthcare Cost and Utilization Project Clinical Classification Software and International Classification of Diseases, Ninth Revision, Clinical Modification codes used to define these variables are listed in eTable 1 in the Supplement.
Outcomes Measured
The primary outcome studied was 30-day all-cause readmission. Readmissions were identified according to the methods outlined by the Healthcare Cost and Utilization Project. 17 For patients who had multiple readmissions within 30 days, only the first readmission was included. Transfer to another hospital was not considered a readmission. To determine the cause of readmission, the primary diagnosis of each readmission record was independently reviewed by 2 authors (S.K. and D.K.) and grouped into clinically relevant categories, as previously described. 16 Discrepancies were resolved by mutual agree- 
Statistical Analysis
Patient demographics, comorbidities, hospital characteristics, in-hospital procedures, and in-hospital complications were compared between low-, medium-, and high-volume hospitals using the Pearson χ 2 test for categorical variables and 1-way analysis of variance for continuous variables. To examine differences in 30-day readmissions among low-, medium-, and high-volume hospitals, multivariable logistic regression models were constructed using generalized estimating equations to account for clustering of outcomes within hospitals. The models included all variables listed in Table 1 (except hospital location because 99.6% were in an urban location) as covariates. We also included the discharge quarter variable in our regression model to partially account for the learning curve associated with TAVR. We performed exploratory analyses comparing 30-day readmission rates between low/medium-vs high-volume hospitals for each quarter of 2014. We also performed a sensitivity analysis using tertiles of annual hospital TAVR volume as cutoff (tertile 1: <74, tertile 2: ≥74 to <143, and tertile 3: ≥143) to determine whether the association between hospital TAVR volume and 30-day readmission rates remained significant. We also examined the association between TAVR volume and 90-day readmission rates. Data were complete for all variables except primary expected payer (0.1% missing) and median household income (1.3% missing). Missing values were replaced with the dominant category for these variables. Data on cost were missing for 308 index hospitalizations and 26 readmissions. Therefore, results of cost analysis are based on a sample size of 15 944 index hospitalizations and 2641 readmissions.
Statistical analysis was performed with IBM SPSS Statistics version 20.0 (IBM Corp). All P values were 2-sided, with a significance threshold of P < .05. Categorical variables are expressed as percentages and continuous variables as mean (SD) or median (interquartile range) as appropriate. Odds ratios (ORs) and 95% CIs are used to report the results of regression analysis.
Results
Of 129 TAVR hospitals included in this study, 20 (15.5%) were categorized as low volume, 47 (36.4%) as medium volume, and 62 (48.1%) as high volume. Of 16 252 index TAVR procedures, 663 (4.1%), 3067 (18.9%), and 12 522 (77.0%) were performed at low-, medium-, and high-volume hospitals, respectively. Table 1 summarizes the baseline characteristics, in-hospital procedures, and in-hospital outcomes of patients who underwent TAVR at low-, medium-, and high-volume hospitals and who were discharged alive. Compared with patients undergo- ing TAVR at low-volume hospitals, those at high-volume hospitals were younger, less likely to be women, and had higher median household income. Patients undergoing TAVR at medium-and high-volume hospitals had a lower burden of comorbidities, especially lower prevalence of diabetes, prior TIA/stroke, anemia, fluid and electrolyte disorders, and neurological disorders compared with those at low-volume hospitals. Patients at medium-and high-volume hospitals were more likely to undergo TAVR via EV access as opposed to more TA TAVRs at low-volume hospitals.
Baseline Characteristics
Rates of complete heart block and permanent pacemaker placement were higher at medium-and high-volume hospitals, whereas low-volume hospitals had a higher incidence of other in-hospital complications such as acute myocardial infarction, cardiac arrest, and major bleeding. Medium-and highvolume hospitals had shorter LOS, lower costs of index hospitalization, and lower rates of discharge to skilled nursing facilities compared with low-volume hospitals.
Incidence of 30-Day Readmissions
The overall incidence of 30-day readmissions was 16.4%. The median time to readmission was 9 days (interquartile range, 5-17 days). There was no significant difference in 30-day readmission rates between low-and medium-volume hospitals Table 2) . For sensitivity analysis, hospitals were divided into tertiles of annual TAVR volume. Thirty-day readmission rates were similar to our absolute volume cutoffs (19.1%, 18.3%, and 15.2% for lowest, middle, and highest tertiles, respectively). Hospitals in the highest-volume tertile were 28% less likely to have a 30-day readmission compared with those in the lowest tertile (adjusted OR, 0.72; 95% CI, 0.63-0.82) (eTable 3 and eFigure 1 in the Supplement). The TAVR volume-readmissions association remained consistent for 90-day readmission rates (eFigure 2 in the Supplement). Results of exploratory analyses comparing 30-day readmission rates between low/ medium-vs high-volume hospitals for each quarter of 2014 are provided in eTable 4 in the Supplement.
Causes of 30-Day Readmissions
Of 2667 readmissions, 1619 (61.7%) were due to noncardiac causes and 1048 (39.3%) were due to cardiac causes. Compared with medium-and high-volume hospitals, low-volume hospitals had a numerically lower proportion of cardiac readmissions (34.4% vs 39.9% vs 39.4%, respectively) and higher proportion of noncardiac readmissions (65.6% vs 60.1% vs 60.6%, respectively); however, this difference was not statistically significant (P = .36) ( Figure 3A) . Among the noncardiac causes of readmission, infection, respiratory, endocrine/ metabolic, renal, and trauma problems were more common in low-volume hospitals, whereas gastrointestinal and TIA/ stroke issues were more common in medium-and highvolume hospitals. Among the cardiac causes, heart failure, arrhythmias, and conduction disorders were more common in medium-and high-volume hospitals, whereas coronary artery disease, chest pain, and syncope were more common in low-volume hospitals ( Figure 3B ). We further categorized causes of readmissions as TAVR-related (cardiac plus noncardiac [bleeding, TIA/stroke, acute kidney injury, postoperative infections, and infections due to cardiac/vascular device]) and non-TAVR-related (all other noncardiac causes). Low-volume hospitals had a higher proportion of non-TAVRrelated readmissions compared with medium-and highvolume hospitals (54.3% vs 45.7% vs 46.9%), but this difference was not statistically significant (P = .21) (eFigure 3 in the Supplement).
LOS and Costs of 30-Day Readmissions
There were no significant differences in the mean LOS and costs of readmission between low-, medium-, and high-volume hospitals (mean [ 
Discussion
Transcatheter aortic valve replacement is the accepted standard of care for appropriately selected patients with symptomatic severe aortic stenosis who are at prohibitive or high surgical risk. The Centers for Medicare and Medicaid Services requires a hospital to perform at least 50 surgical aortic valve replacements (including for at least 10 high-risk patients), employ 2 or more physicians with cardiac surgery privileges, and perform 1000 or more coronary angiograms (≥400 percutaneous coronary interventions) prior to approval as a TAVR site.
19 Preexisting hospital volume (interventional and surgical) and available physician resources play a key role not only in the initial approval, but also on program maintenance and reimbursements. It underlines the importance given to hospital volumes in predicting patient outcomes. In our analysis, we report several novel findings: (1) there was an inverse association between hospital TAVR volume and 30-day readmission rates; (2) noncardiac readmissions were more common in low-volume hospitals, whereas cardiac readmissions were more common in high-volume hospitals; and (3) there were no differences between mean LOS and costs of readmissions between high-, medium-, and low-volume hospitals. Although the cost of all readmissions was similar, lower readmission rates at high-volume hospitals equate to lower health care costs and substantial savings. Readmission is an important metric not only for reimbursement purposes, but also for tracking the outcomes of any novel procedure. The 30-day readmission rate for 6 surgical procedures (coronary artery bypass graft surgery, pulmonary lobectomy, EV repair of abdominal aortic aneurysm, open repair of abdominal aortic aneurysm, colectomy, and hip replacement) using Medicare data was 13.1%. 20 More importantly, for these surgical procedures, the highest-volume hospitals had the lowest readmissions rates when compared with the lowest-volume hospitals (12.7% vs 16.8%; P < .001). We report a 25% lower readmission rate in high-volume hospitals (≥100 TAVRs annually) compared with low-volume hospitals (<50 TAVRs annually). Prior to this study, to our knowledge, there were no data on the association between TAVR hospital volume and 30-day readmission rates. Murugiah et al 22 used Medicare data to understand the relationships between hospitals' all-cause readmission rate and their 30-day TAVR patient readmission rate. In their analysis, the odds of 30-day readmission was 1.41 (95% CI, 1.37-1.44) when the patient was treated at a hospital 1 SD above the national average for 30-day all-cause readmissions vs a hospital 1 SD below the national average for 30-day all-cause readmissions.
22
The authors postulated that hospital and system factors may play a key role in this observed variation. However, one of the limitations of their study was the lack of assessment of the relationship between hospital TAVR volume and outcomes. The inverse association between hospital TAVR volume and 30-day readmission rates seen in our study is potentially of concern. Low-volume hospitals were more likely to operate on patients with a higher number of comorbidities compared with high-volume hospitals and were more likely to use the TA approach. Transapical TAVR is associated with poorer short-and intermediate-term mortality, increased use of skilled nursing care facilities, longer hospital stays, and readmissions when compared with transfemoral TAVR. 16, [24] [25] [26] Transapical TAVR is associated with lower risk for vascular complications and is useful in patients with severe extensive peripheral vascular disease. However, in our analysis, preexisting peripheral vascular disease was similar in both groups. It is possible that the TA approach was used more frequently at low-volume sites owing to physician preference rather than patient factors alone. Alternatively, because these data were collected at the time of rapid technology evolution and development of lower profile systems, there is a possibility that higher-volume hospitals had greater access to newer technological advancements in EV access. Higher rates of complete heart block and permanent pacemaker placement at medium-and high-volume hospitals may be due to valve selection or a lower threshold to place a pacemaker during the index hospitalization rather than specific approach (TA TAVR vs EV TAVR).
5,27,28
Patient population and community resources can also affect the readmission rate and are difficult to assess from this study.
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The British Columbia TAVR program recently reported its success by using regional systems of care and demonstrated shorter median hospital stays (3 days vs 5 days in TVT high-risk and TVT inoperable registries) and higher rates of discharge to home (94% compared with 67% in TVT high-risk and 70% in TVT inoperable registries). 30 Regionalization of TAVR care may improve outcomes including lowering readmission rates. For example, referrals for extremely complex patients and TA TAVRs can be made to a single high-volume site in the region or county, whereas the less complex TAVR cases using the EV approach may be performed at lower-volume hospitals. Although our data are hypothesis generating, they do not provide sufficient argument to advocate for regionalization of TAVR care in the United States as TAVR is a maturing field. The procedure was evolving at the time of data acquisition. There is a learning curve for all new procedures and lower-volume hospitals in 2014 that may have been on the learning curve could now represent the high-volume hospitals. 31,32 It took 26 cases to achieve a consistently low risk for 30-day major adverse events according to a post-hoc analysis of the Placement of Aortic Transcatheter Valves 1 Trial. 31 Learning curve is more pertinent to low-volume hospitals and we tried to partially account for it by adjusting for discharge quarter in our multivariate models. We observed a learning curve effect, ie, difference in readmission rates between low/medium-and high-volume hospitals narrowed with increasing experience (first quarter to fourth quarter); however, the volume-readmission association still remained significant. The decline in readmission rates per quarter was greater for low/medium-volume hospitals (supporting a learning curve effect); however, even the high-volume hospitals showed a significant decline in readmission rates per quarter (supporting the inverse association between volume and readmissions even in highly experienced hospitals). As both investigational and commercial TAVR implants were included in the NRD databases, it is possible that the higher-volume hospitals had greater access to EV technologies leading to greater use of EV TAVR. In our previously published study, 16 the most common causes of readmission after TAVR were noncardiac (61.8%). The predictors of 30-day readmissions were longer LOS, acute kidney injury, chronic kidney disease, TA TAVR, more than 4 Elixhauser comorbidities, chronic lung disease, and discharge to a skilled nursing facility. 16 Higher respiratory and infectious etiology of noncardiac readmissions at low-volume hospitals seen in the present study may be due to prolonged intensive care unit stays (owing to more TA TAVRs), greater use of general anesthesia, and surgical femoral artery cut down for transfemoral TAVR cases. 33,34 Thirty-day readmissions due to heart failure and arrhythmias were more common at high-volume hospitals. Potentially, the drivers of the observed inverse hospital volume-30-day readmissions association are patient comorbidities, TAVR-approach selection, proficiency in EV TAVRs by more experienced operators at higher-volume hospitals (operator factors), and better postoperative care coordination at higher-volume hospitals. It is difficult to control the composition of patient population and local community resources for the hospital systems, but hospital volume, health care systems, physician expertise, and postoperative care coordination are modifiable targets for standardizing outcomes. As more TAVR programs open in the country catering to intermediate-to higher-risk subgroups, these data become even more meaningful in guiding appropriate strategies to reduce readmission rates and health care costs.
Limitations
The NRD is an administrative database and information on valve type and size, echocardiographic variables, postprocedural paravalvular leak, individual patient risk scores, and medication use are not available. Society of Thoracic Surgeons scores were not available in NRD databases. Endovascular TAVR access includes all percutaneous approaches and we were unable to differentiate between femoral, direct aortic, subclavian, iliac, caval, and carotid access using the NRD databases. Readmissions across states are not captured by NRD. Post-TAVR patients will rarely be admitted to an out-of-state hospital, making this limitation relatively inconsequential. However, 30-day readmissions have been reported using administrative databases in prior studies. 16, 22, 23 Mortality after discharge is not captured in the NRD and this is a limitation as hospitals with high mortality rates may have a lower readmission rate. However, in-hospital mortality was lowest in high-volume hospitals and we expect this to hold true even after discharge. Residual measured and unmeasured confounding may be present in the adjusted analyses. Causes of readmission may be subject to misattribution; however, the NRD is robust in evaluating noncardiac causes of readmissions and cost analysis when compared with other available clinical registries.
Conclusions
Using a large national readmission database, we report an inverse association between hospital TAVR volume and 30-day readmissions. The reason for this inverse association is likely multifactorial and depends on patient factors, operator factors, hospital systems, and community factors. Low-volume hospitals had a higher proportion of noncardiac readmissions (infections and respiratory) compared with high-volume hospitals, likely driven by patient factors and procedural approach selection. There were no differences in LOS and cost of readmissions between low-, medium-, and high-volume hospitals.
Lower readmission rates at high-volume hospitals substantially reduce health care expenditure. As new TAVR programs open across the country, these data will guide policy makers to identify targets for optimizing and standardizing TAVR outcomes across hospitals. The rational dispersion of this technology has been a consistent concern since it was first approved for commercial use. How should patient access to this life-changing procedure be balanced against the need to promote the highest-quality care and insure optimal outcomes? Strategies used to address this challenge have included linkage of site selection criteria to Centers for Medicare & Medicaid Services reimbursement, US Food and Drug Administration indications for use labeling, institutional and operator requirements recommended by professional societies, and medical device company support. Participation in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry (NCT01737528) is a requisite. The cumulative experience with TAVR is now robust enough to carefully examine not only survival and functional outcomes, but also the processes of care and measures of efficiency and quality that define best practices. It is inevitable that the conversation will turn to questions such as whether there are too many, too few, or just the right number of individual hospitals and whether alternative models of integrated care across hospitals should be considered, especially as the field of transcatheter therapies continues to evolve.
There is an inverse association between TAVR hospital volume and in-hospital death, vascular complications, and bleeding. 1 In this issue of JAMA Cardiology, Khera and colleagues 2 describe an inverse association between TAVR hospital volumes and 30-day readmission rates. Despite the controversies surrounding the readmission rate metric, scrutiny of processes designed to optimize transitions of care should be promoted. Reports of this nature can inform policy discussions regarding dissemination of high-impact expensive technologies. Prior efforts to limit high-risk surgical procedures to higher-volume hospitals/operators were met with vigorous pushback.
3 Nevertheless, there is widespread acknowledgment that a prospective, multistakeholder conversation regarding a health systems approach to treating patients with valve disease, much like that espoused by the Brain Attack Coalition for acute stroke, 4 is necessary. 
